Medicenna Therapeutics Corp
TSX:MDNA
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The company went IPO on 2015-07-13. The firm is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company’s product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The firm has not earned any revenues from its products.
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The company went IPO on 2015-07-13. The firm is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company’s product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The firm has not earned any revenues from its products.
Trial Progress: Medicenna advanced its Phase 1/2 ABILITY study of MDNA11 to the sixth dose escalation cohort, reflecting favorable tolerability and continued immune activation.
Safety Profile: MDNA11 has shown no dose-limiting toxicities, interruptions, de-escalations, or discontinuations due to safety issues so far.
Promising Efficacy Signals: Early antitumor activity was observed, including tumor control in 36% of evaluable patients and a partial response in a difficult-to-treat pancreatic cancer case.
Upcoming Milestones: Key clinical data readouts are expected later this quarter and throughout 2023, including updates from the ongoing dose escalation and early Phase 2 expansion cohorts.
Financial Position: Cash and equivalents stood at CAD36.2 million as of December 31, 2022, providing runway through Q2 2024.
Bizaxofusp (MDNA55) Update: Positive Phase 2b data were published and discussions continue regarding potential partnerships for further development.
